Navigation Links
New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory,Properties and Increased Health Benefits

- Bifantis shows ability to limit inflammation in models of arthritis and Salmonella infection, according to data presented at Digestive Disease Week -

WASHINGTON, May 21, 2007 /PRNewswire/ -- The biotechnology company Alimentary Health today announced results from two studies that demonstrate the anti-inflammatory activity of a natural probiotic bacterial strain of human origin, Bifantis(R) (Bifidobacterium infantis 35624), in models of arthritis and Salmonella infection. Data from these studies were presented this week at the 38th annual Digestive Disease Week (DDW) conference taking place in Washington D.C.

The inflammatory response is a key part of the immune system's battle against invaders, but in certain conditions and diseases, it can do more harm than good by injuring healthy tissue. Inflammation is associated with a variety of conditions, such as inflammatory bowel disease, arthritis, cardiovascular disease, diabetes, Alzheimer's disease and more. Bifantis has previously been shown to modulate the inflammatory response in a clinical trial in irritable bowel syndrome. The results announced this week demonstrate that the anti-inflammatory effects of Bifantis are not restricted to the gastrointestinal tract.

"Inflammation is a major factor in a number of chronic diseases, which affect millions of people," said Barry Kiely, Chief Executive Officer, Alimentary Health and an early investigator of the probiotic effects of Bifantis. "Data continue to show that Bifantis has anti-inflammatory activity, which may be useful in the management of inflammation-linked diseases."

In one of the studies released today, four bacterial strains were fed to mice. Of these four strains, researchers determined that only Bifantis delayed the onset of artificially induced arthritis and resulted in less severe arthritic symptoms. This study represents some of the latest work assessing the link between diet i
'"/>




Page: 1 2 3

Related medicine technology :

1. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
2. New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus
3. NanoViricides Drugs Found To Be Highly Effective Against Most Recent Strain of the H5N1 Avian Flu Virus
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
7. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
8. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
9. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
10. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
11. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
Post Your Comments:
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... PALO ALTO, Calif., March 8, 2011 Jazz Pharmaceuticals, Inc. ... will be providing a business update at two upcoming investor ... financial officer, will provide an update at the ROTH 23rd ... Monday, March 14, 2011 at 4:30 p.m. Pacific Time ...
... Warner Chilcott plc (Nasdaq: WCRX ) ... its ordinary shares by certain selling shareholders. The selling ... Morgan Partners (advised by CCMP Capital) and Thomas H. ... management. The offering is being conducted as a public ...
Cached Medicine Technology:Warner Chilcott Announces Secondary Equity Offering 2Warner Chilcott Announces Secondary Equity Offering 3Warner Chilcott Announces Secondary Equity Offering 4
(Date:4/17/2014)... The presence of chronic inflammation in benign prostate ... cancer, and this association was found even in ... to a study published in Cancer Epidemiology, ... American Association for Cancer Research. , An analysis ... of the placebo arm of the Prostate Cancer ...
(Date:4/17/2014)... specifically associated with the risk of a difficult-to-diagnose ... of all breast cancer cases. , The largest ... invasive lobular carcinoma, gives researchers important clues to ... breast cancer, which can be missed through screening. ... journal PloS Genetics , was co-led by ...
(Date:4/17/2014)... popular vaccine brands for children may not be the ... cost factors when choosing vaccines, driving the market toward ... a new study by University of Illinois researchers. , ... by numerous factors," says Sheldon H. Jacobson, a co-author ... and of mathematics at the U. of I. "In ...
(Date:4/17/2014)... Biology and Medicine a multidisciplinary research team ... in the Institute of Genomic Biology (IGB) on ... describe their recent work on subcellular redox homeostasis. ... functions including energy metabolism, signaling, and transcriptional processes. ... cellular behavior, redox status has been recognized as ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study recalculates costs of combination vaccines 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:CU researchers discover target for treating dengue fever 2
... ... implicate the purchaser in any lawsuit or cause such purchasers to be a party ... ... highly respected developer and manufacturer of proprietary skin care formulations, who also is the ...
... ... latest version of its revolutionary cost-cutting software. Newly developed upgrades to iCodeRx, iDocs, and ... processes, while providing the highest security possible to patient information. , ... Virginia Beach, VA (PRWEB) - DOMA ...
... ... a new agreement with B. E. Smith for Executive Leadership Solutions. , ... Lenexa, KS (Vocus) September 24, ... agreement with B. E. Smith for Executive Leadership Solutions., , ,Effective immediately, through August ...
... trials, advanced cancers shrunk rapidly, researchers say , THURSDAY, ... advanced melanoma promotes rapid shrinking of tumors, according to ... includes patients with the cancer-causing mutation of the BRAF ... melanomas and 5 percent of colorectal cancers. , The ...
... say , THURSDAY, Sept. 24 (HealthDay News) -- Surgery ... carpal tunnel syndrome who don,t have severe nerve damage ... 44 patients who had surgery and 52 patients who ... A year after treatment, the patients, hand function was ...
... drugs increase the possibility of septal malformation, researchers find ... who take certain antidepressants during the first three months ... giving birth to babies with heart defects. , Septal ... right side of the heart from the left -- ...
Cached Medicine News:Health News:Purchase PHYTO-C Skincare Will Not Implicate in the Lawsuit 2Health News:DOMA Transforms Healthcare IT with Increased Security While Reducing Cost -- iCodeRx/iDocs/iCharts 6.0 Debuts at AHIMA National Convention 2Health News:DOMA Transforms Healthcare IT with Increased Security While Reducing Cost -- iCodeRx/iDocs/iCharts 6.0 Debuts at AHIMA National Convention 3Health News:Members to Benefit from New Agreement between Amerinet and B. E. Smith 2Health News:New Treatment May Beat Melanoma 2Health News:New Treatment May Beat Melanoma 3Health News:Surgery Best for Carpal Tunnel Syndrome 2Health News:Surgery Best for Carpal Tunnel Syndrome 3Health News:Antidepressants Linked to Heart Defects in Newborns 2Health News:Antidepressants Linked to Heart Defects in Newborns 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: